The API5 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the API5 gene in the human embryonic kidney cell line HEK293T. This model was generated through transient transfection of CRISPR/Cas9 components, resulting in a heterogeneous mixture of gene-edited alleles. The polyclonal format maintains cellular heterogeneity and avoids clonal artifacts, providing a robust system for investigating the role of API5 in apoptosis regulation and survival signaling across a diverse genetic background.
The HEK293T host cell line is derived from adenovirus 5-transformed human embryonic kidney epithelial cells and stably expresses the SV40 large T-antigen, which enables high transfection efficiency and episomal plasmid replication. These adherent cells are widely used for recombinant protein expression and lentiviral vector production due to their rapid growth and genetic tractability. The renal epithelial origin of HEK293T offers a physiologically relevant platform for studying molecular pathways that govern apoptosis, cell migration, and cancer cell survival.
API5 encodes an anti-apoptotic protein that directly binds to Acinus (ACIN1) and prevents its cleavage by caspase-3, thereby inhibiting chromatin condensation and DNA fragmentation. API5 is transcriptionally regulated by SP1, E2F1, and NF-Y, and its expression is modulated by the PI3K/Akt survival pathway. Through interactions with PSF and SART3, API5 promotes cell viability and migration. Disruption of API5 by CRISPR/Cas9 removes a critical survival signal, sensitizing cells to E2F1-dependent apoptosis and providing a model to dissect these interconnected regulatory mechanisms.
Using gene-disrupted HEK293T cells as a polyclonal pool is especially informative because these cells natively express API5 and support high-efficiency downstream assays. The mixed knockout population allows researchers to evaluate dose-dependent effects of pathway inhibitors, perform rescue experiments by re-expressing wild-type or mutant API5, and study migration phenotypes without the bias of monoclonal selection. The inherent heterogeneity mimics the genetic diversity found in tumors, making the model highly relevant for validating API5 as a drug target in colorectal, breast, and other carcinomas.
These knockout cells are broadly applicable in apoptosis research; typical assays include Annexin V/propidium iodide flow cytometry for apoptosis quantification, luminescence-based caspase-3/7 activity detection, wound healing or transwell migration assays, and MTT viability tests under drug treatment. The cells can also be used for co-immunoprecipitation to probe API5?CACIN1 interactions, immunofluorescence localization of key partners, and transcriptome-wide RNA-seq analysis. Furthermore, they enable functional validation of candidate drugs that target the PI3K/Akt or E2F1 pathways. For technical inquiries, please contact Ascent Research.
